Nicholas M Anstey Selected Research

Primaquine

11/2020	The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia.
4/2019	Safety of primaquine in infants with Plasmodium vivax malaria in Papua, Indonesia.
1/2019	The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.
1/2019	High Risk of Plasmodium vivax Malaria Following Splenectomy in Papua, Indonesia.
1/2018	The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis.
8/2017	Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study.
3/2017	Genotypic and phenotypic characterization of G6PD deficiency in Bengali adults with severe and uncomplicated malaria.
1/2012	Chemotherapeutic strategies for reducing transmission of Plasmodium vivax malaria.
12/2011	Plasmodium vivax treatments: what are we looking for?
5/2011	Plasmodium knowlesi malaria in children.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nicholas M Anstey Research Topics

Disease

104	Malaria 10/2022 - 01/2002
53	Falciparum Malaria (Plasmodium falciparum Malaria) 10/2022 - 07/2002
47	Infections 10/2022 - 12/2002
26	Vivax Malaria 01/2022 - 12/2002
19	Parasitemia 01/2021 - 09/2002
16	Hemolysis 10/2022 - 10/2007
13	Cerebral Malaria 10/2021 - 02/2003
13	Sepsis (Septicemia) 04/2018 - 05/2004
8	Anemia 04/2020 - 05/2005
7	Acute Kidney Injury (Acute Renal Failure) 10/2022 - 06/2015
7	Melioidosis 01/2020 - 09/2003
7	Tuberculosis (Tuberculoses) 01/2019 - 07/2008
6	Fever (Fevers) 10/2020 - 09/2002
5	Hyperemia 11/2016 - 11/2008
4	Septic Shock (Toxic Shock Syndrome) 12/2021 - 01/2004
4	Pneumonia (Pneumonitis) 01/2020 - 09/2003
4	Glucosephosphate Dehydrogenase Deficiency 01/2019 - 12/2011
3	Coma (Comas) 10/2021 - 02/2013
3	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 10/2020 - 12/2005
3	Thrombocytopenia (Thrombopenia) 04/2020 - 01/2015
3	Convalescence 01/2020 - 07/2013
3	Pulmonary Tuberculosis 01/2017 - 01/2013
3	Inflammation (Inflammations) 01/2017 - 01/2015
3	Critical Illness (Critically Ill) 12/2013 - 01/2010
3	Acidosis 03/2010 - 08/2002
2	Acute malaria 01/2020 - 06/2009
2	Hypoxia (Hypoxemia) 03/2019 - 02/2013
2	Bacterial Infections (Bacterial Infection) 01/2018 - 01/2016
2	Disease Progression 01/2017 - 09/2002
2	Vascular Diseases (Vascular Disease) 10/2014 - 02/2011
2	Communicable Diseases (Infectious Diseases) 08/2014 - 02/2010
2	Ischemia 02/2013 - 10/2007

Drug/Important Bio-Agent (IBA)

34	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2021 - 01/2002
19	Pharmaceutical PreparationsIBA 01/2022 - 07/2002
19	Chloroquine (Aralen)FDA LinkGeneric 01/2021 - 07/2002
19	Arginine (L-Arginine)FDA Link 01/2019 - 02/2003
18	artemisinin (artemisinine)IBA 01/2021 - 12/2002
17	ArtesunateIBA 01/2021 - 12/2002
15	Hemoglobins (Hemoglobin)IBA 10/2022 - 05/2005
15	Antimalarials (Antimalarial Agents)IBA 01/2020 - 09/2002
12	Nitric Oxide Synthase (NO Synthase)IBA 01/2016 - 11/2002
11	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2005
11	Primaquine FDA Link 11/2020 - 10/2009
8	CytokinesIBA 02/2021 - 09/2002
8	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 09/2003
8	Lactic Acid (Lactate)FDA LinkGeneric 03/2019 - 10/2007
7	AntibodiesIBA 01/2022 - 09/2002
7	piperaquineIBA 12/2021 - 10/2012
7	artenimol (dihydroartemisinin)IBA 12/2021 - 10/2012
7	Interleukin-10 (Interleukin 10)IBA 01/2019 - 05/2005
6	Immunoglobulin G (IgG)IBA 01/2022 - 09/2002
6	VaccinesIBA 01/2022 - 08/2006
6	N,N-dimethylarginine (asymmetric dimethylarginine)IBA 01/2021 - 04/2010
6	HLA-DR Antigens (HLA-DR)IBA 01/2020 - 08/2015
6	Angiopoietin-2IBA 06/2018 - 11/2008
5	CreatinineIBA 10/2022 - 05/2005
5	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2008
5	AntigensIBA 01/2018 - 06/2009
5	Histidine (L-Histidine)FDA Link 01/2018 - 01/2012
4	Acetaminophen (Paracetamol)FDA LinkGeneric 10/2022 - 01/2018
4	Glucosephosphate Dehydrogenase (Glucose 6 Phosphate Dehydrogenase)IBA 04/2019 - 03/2017
4	Oxygen (Dioxygen)IBA 03/2019 - 02/2013
4	Amino Acids FDA Link 01/2019 - 06/2006
4	Interleukin-6 (Interleukin 6)IBA 01/2017 - 07/2010
4	ArginaseIBA 01/2016 - 04/2014
3	RNA (Ribonucleic Acid)IBA 01/2020 - 01/2017
3	Complement System Proteins (Complement)IBA 11/2019 - 11/2018
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019 - 05/2005
3	EnzymesIBA 06/2017 - 02/2010
3	Vitamin D FDA LinkGeneric 01/2017 - 07/2008
3	L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA 01/2015 - 04/2013
2	Plasmodium falciparum erythrocyte membrane protein 1IBA 01/2022 - 05/2016
2	PterinsIBA 10/2021 - 03/2015
2	OsteoprotegerinIBA 01/2020 - 06/2018
2	InterferonsIBA 01/2020 - 01/2011
2	Immunoglobulin M (IgM)IBA 01/2019 - 09/2002
2	Lumefantrine Drug Combination Artemether (Coartem)FDA Link 01/2018 - 01/2017
2	KynurenineIBA 01/2017 - 01/2011
2	Mefloquine (Lariam)FDA LinkGeneric 02/2016 - 01/2016
2	Interleukin-12 (IL 12)IBA 01/2016 - 11/2003
2	Messenger RNA (mRNA)IBA 01/2016 - 08/2014
2	BiopterinsIBA 03/2015 - 03/2015
2	Intercellular Adhesion Molecule-1 (Intercellular Adhesion Molecule 1)IBA 03/2015 - 07/2010
2	Phenylalanine (L-Phenylalanine)FDA Link 03/2015 - 06/2006
2	7,8-dihydrobiopterinIBA 03/2015 - 03/2015
2	sapropterin (tetrahydrobiopterin)FDA Link 03/2015 - 03/2015
2	E-SelectinIBA 01/2015 - 07/2010
2	Quinine (Quinson)FDA Link 01/2014 - 06/2008
2	Essential Amino AcidsIBA 02/2011 - 01/2011
2	Lymphotoxin-alpha (Lymphotoxin)IBA 10/2010 - 07/2010
2	Bicarbonates (Hydrogen Carbonate)IBA 03/2010 - 09/2003
2	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 02/2010 - 12/2003
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2010 - 11/2008

Therapy/Procedure

33	Therapeutics 01/2021 - 12/2002
8	Aftercare (After-Treatment) 01/2022 - 05/2002
3	Splenectomy 01/2021 - 09/2016
3	Blood Transfusion (Blood Transfusions) 07/2016 - 11/2014
2	Renal Replacement Therapy (Therapies, Renal Replacement) 01/2017 - 01/2015
2	Length of Stay 12/2015 - 02/2008
2	Resuscitation 01/2015 - 11/2014